Plasmin and other fibrinolytic proteases

Plasmin and other fibrinolytic proteases, such as tissue-type plasminogen activator (tPA) and urokinase (uPA), constitute the enzymatic system responsible for the degradation of fibrin clots (fibrinolysis) to maintain blood flow (StatPearls, 2023). Plasmin, the central enzyme of this pathway, is a serine protease derived from the zymogen plasminogen (UniProt P00747). This system plays a critical role in physiological processes including wound healing, tissue remodeling, and cell migration (PubMed, PMC2825079). Pathologically, overactivity of these proteases can lead to hyperfibrinolysis and hemorrhage, while underactivity contributes to thrombotic disorders like deep vein thrombosis, pulmonary embolism, and ischemic stroke (NIH, 2022). Therapeutic strategies leverage this system by using recombinant tPA (e.g., Alteplase) as a thrombolytic agent to dissolve clots during acute vascular events (DrugBank DB00009). Conversely, antifibrinolytic drugs like tranexamic acid are used to inhibit plasmin activity and reduce blood loss in surgery or trauma (DrugBank DB00302). Beyond coagulation, these enzymes are implicated in cancer progression by facilitating basement membrane degradation and tumor cell invasion (PubMed, PMID: 12097102). Overall, this protease group represents a vital target for managing both acute thrombotic emergencies and chronic inflammatory or neoplastic conditions.

Other names

Fibrinolytic systemPlasminogen systemThrombolytic enzymesFibrinolytic cascade

Thrombolytic drugs function as plasminogen activators that catalyze the conversion of plasminogen to plasmin, which then cleaves fibrin into soluble degradation products (StatPearls, 2023). Antifibrinolytic agents, such as lysine analogs (e.g., tranexamic acid), competitively inhibit the binding of plasminogen and plasmin to fibrin, thereby preventing clot dissolution (DrugBank DB00302). Direct inhibitors like aprotinin work by blocking the active site of the plasmin enzyme itself (DrugBank DB00039).